Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome.
T Banasiewicz, Ł Krokowicz, Z Stojcev...
https://pubmed.ncbi.nlm.nih.gov/22738315Actively Recruiting
Phase Not Applicable
Age: 18Years +
FEMALE
ID06653426
The Effect of Sodium Butyrate on Menstrual Symptoms in Women
Led by Magdy Milad, MD · Updated on 2026-04-29
15
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to study the effects of Sodium Butyrate (NaBu), a dietary supplement, on menstrual symptoms in women. The study focuses on common symptoms such as abdominal or pelvic cramping, lower back pain, bloating, mood swings, and irritability, which are thought to be linked to estrogen production in certain cells. Researchers believe that NaBu may reduce these symptoms by inhibiting a key enzyme involved in estrogen synthesis. Participants will take 2.4 grams of Sodium Butyrate daily in tablet form for 12 weeks. They will self-administer the supplement and record their daily symptom severity using an electronic diary. The study compares symptom scores recorded before starting NaBu with those during the 12-week treatment to evaluate changes. During the study, participants will have regular follow-ups to monitor progress and any side effects. Researchers will measure changes in average menstrual symptom scores between the baseline period (one menstrual cycle before starting NaBu) and the treatment period. The total participation involves daily symptom tracking and supplement use over 12 weeks.
CONDITIONS
Brief Title
The NaBu Effect on Menstruation in Women
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Currently menstruating regularly or irregularly
- Experiencing menstrual symptoms with an average baseline severity score of at least 3 out of 10 for at least one symptom during the initial rating period
You will not qualify if you...
- Pregnant or breastfeeding, or planning to become pregnant
- History of bloating or sensitive gut requiring low fiber intake
- Known lactose intolerance, FODMAP intolerance, or small intestinal bacterial overgrowth (SIBO)
- Requires daily antacids during the study
- Known or suspected chronic hypertension
- Post-menopausal status
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 12 weeks
Participants self-administer Sodium Butyrate (NaBu) daily for 12 weeks to evaluate its effect on menstrual symptoms. They maintain an electronic diary (eDiary) to record daily symptom severity during this period.
Daily self-administration and symptom recording via eDiary
Trial Site Locations
Total: 1 location
1
Northwestern University - Northwestern Medicine, Lavin Family Pavilion
Chicago, Illinois, United States, 60611
Actively Recruiting
Loading map...
Research Team
J
juan A avitia, MS
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts.
Santanu Deb, Jianfeng Zhou, Sanober A Amin...
https://pubmed.ncbi.nlm.nih.gov/16303757Maternal sodium butyrate supplement elevates the lipolysis in adipose tissue and leads to lipid accumulation in offspring liver of weaning-age rats.
Jiabin Zhou, Shixing Gao, Jinglong Chen...
https://pubmed.ncbi.nlm.nih.gov/27449927Butyric acid - a well-known molecule revisited.
Katarzyna Borycka-Kiciak, Tomasz Banasiewicz, Grażyna Rydzewska
https://pubmed.ncbi.nlm.nih.gov/28702095Butyric acid in irritable bowel syndrome.
Andrzej Załęski, Aleksandra Banaszkiewicz, Jarosław Walkowiak
https://pubmed.ncbi.nlm.nih.gov/24868283Aromatase--a brief overview.
Evan R Simpson, Colin Clyne, Gary Rubin...
https://pubmed.ncbi.nlm.nih.gov/11826265Aromatase and other steroidogenic genes in endometriosis: translational aspects.
E Attar, S E Bulun
https://pubmed.ncbi.nlm.nih.gov/16123052